|
Report Date : |
07.05.2013 |
IDENTIFICATION DETAILS
|
Name : |
BARRETT HODGSON PAKISTAN (PRIVATE) LTD |
|
|
|
|
Registered Office : |
F-423, S.I.T.E., Karachi |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Year of Establishments: |
1992 |
|
|
|
|
Com. Reg. No.: |
0028289 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of Pharmaceutical Products |
|
|
|
|
No. of Employees : |
288 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Pakistan |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Pakistan ECONOMIC OVERVIEW
Decades of
internal political disputes and low levels of foreign investment have led to
slow growth and underdevelopment in Pakistan. Agriculture accounts for more
than one-fifth of output and two-fifths of employment. Textiles account for
most of Pakistan's export earnings, and Pakistan's failure to expand a viable
export base for other manufactures has left the country vulnerable to shifts in
world demand. Official unemployment is under 6%, but this fails to capture the
true picture, because much of the economy is informal and underemployment
remains high. Over the past few years, low growth and high inflation, led by a
spurt in food prices, have increased the amount of poverty - the UN Human
Development Report estimated poverty in 2011 at almost 50% of the population.
Inflation has worsened the situation, climbing from 7.7% in 2007 to almost 12%
for 2011, before declining to 10% in 2012. As a result of political and
economic instability, the Pakistani rupee has depreciated more than 40% since
2007. The government agreed to an International Monetary Fund Standby
Arrangement in November 2008 in response to a balance of payments crisis.
Although the economy has stabilized since the crisis, it has failed to recover.
Foreign investment has not returned, due to investor concerns related to
governance, energy, security, and a slow-down in the global economy.
Remittances from overseas workers, averaging about $1 billion a month since
March 2011, remain a bright spot for Pakistan. However, after a small current
account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current
account turned to deficit in fiscal year 2012, spurred by higher prices for
imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income,
low-growth trap, with growth averaging about 3% per year from 2008 to 2012.
Pakistan must address long standing issues related to government revenues and
energy production in order to spur the amount of economic growth that will be
necessary to employ its growing and rapidly urbanizing population, more than
half of which is under 22. Other long term challenges include expanding
investment in education and healthcare, adapting to the effects of climate
change and natural disasters, and reducing dependence on foreign donors.
|
Source : CIA |
BARRETT HODGSON PAKISTAN (PRIVATE) LTD
|
Registered Address
& Factory |
|
F-423, S.I.T.E.,
Karachi, Pakistan |
|
Tel # |
92
(21) 32570651 - 57 (7 Lines) |
|
Fax # |
92
(21) 32568827, 32570650 |
|
a. |
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
b. |
Year Established |
1992 |
|
c. |
Registration # |
0028289 |
|
Address |
1-A, Shahid Plaza, Jinnah Avenue, Blue Area, Islamabad,
Pakistan |
|
Tel # |
92 (51) 2277098, 2270275 |
|
Fax # |
92 (51) 2270277 |
|
Address |
175, Gen. Sarfraz Khan Road, Shadman-II, Lahore, Pakistan |
|
Tel # |
92 (42) 37562711,
37562705 |
|
Fax # |
92 (42) 37582854 |
A.F. Ferguson & Co.
(Chartered
Accountants)
State Life Building, 1-C, Off: I.I. Chundrigar Road,
Karachi, Pakistan
Subject Company was established as a Private Limited Company
in 1992
|
Authorized Capital |
Rs. 250,000,000/-
divided into 2,500,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 136,570,000/-
divided into 1,365,700 shares of Rs. 100/- each |
|
Names |
Nationality |
Address |
Designation |
|
Dr. Iram Afaq Mr. Tariq Amin Dr. M.S. Habib Mr. Shahid Mansoor Dr. Hasan Tharani Mr. S. Shakeel Ahmed |
Pakistani Pakistani Pakistani Pakistani Pakistani Pakistani |
166,
Khayaban-e-Shahbaz, Phase VI, DHA, Karachi House No. 34/II, Khayaban-e-Badar, Phase-V, DHA, Karachi 166, Khayaban-e-Shahbaz, Phase VI, DHA, Karachi House No. C-55, Block 9, Gulshan-e-Iqbal, Karachi B-112, Block-10, Gulshan-e-Iqbal, Karachi D/17, Askari-IV,
Apartment, Rashid Minhas Road, Karachi |
Chief Executive Director Director Director Director Director |
|
Names |
No. of Shares |
|
Barrett Hodgson Limited, U.K. Dr. M.S. Habib Mr. Benyamin Naeem Habib Dr. Iram Afaq |
1,207,279 57,599 100,821 1 |
A. Subsidiary
None
B. Associated
Companies
(1) Lahore Medical Instruments (Pvt) Limited, Pakistan.
Manufacture & marketing of different pharmaceutical
class like Anti Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine, Narcotic
Analgesic, Non Steroidal Respiratory Anti Inflamatory, Quinolones, Vitamins,
Phenothiazine, Hypolipidaemics, Muscle Relaxant, Amoebicide,
Calcium-Antagonist, Cardio Selective Beta Blocker with their brand names of ACICON, BAMBEC, BAYHEP, BETALOC ZOK,
BETAXEN, BINADEX, BRICANYL, CEFAMEZIN, CEFCOM, CEFIX, CEFIZOX, CEFNIR, CEFSPAN,
CIPOCAINE, CIPOTIC, DOMEL, DYNAQUIN, ERADEP, EXOCIN, FEBROL, FLUCOL, GENTICYN,
GIXER, INOCEF, INOQUIN, JECTOFER, LEVAQUIN, MOBIKARE GEL, MST CONTINUS, MYLAXON,
OCUFEN, PENGLOBE, PERSCH, PLENDIL, POLYFER, PRED FORTE, PULMICORT, QUINTEC,
RECOL, ROMICEF, SARTAN, WINTAX, XYLOAID, XYLOCAINE, ADRENALINE
288
The capacity and production of the company’s plant is
indeterminable as it is multi-product and involves varying processes of
manufacture
|
Year |
In Pak Rupees |
|
2011 |
520,000,000/- (Estimated) |
(Foreign)
ASTRAZENECA, U.K.
ASTELLAS DEUTSCHLAND GMBH, GERMANY.
MIKA PHARMA GMBH, GERMANY.
ALLERGAN, U.S.A.
ZHEJIANG JINGXIN PHARMACEUTICAL IMPORT & EXPORT, CHINA.
More than 100
Distributors in all over Pakistan
Mainly to Asian, Middle East and European Countries
· Faysal Bank Limited, Pakistan.
· Habib Bank Limited, Pakistan.
· Habib Metropolitan Bank Limited, Pakistan.
· Standard Chartered Bank, Pakistan.
· Saudi Pak Commercial Bank Limited, Pakistan.
· ABN AMRO Bank, Pakistan.
·
Pakistan Pharmaceutical Manufacturers
Associations.(PPMA)
·
Karachi Chamber of Commerce & Industry.(KCCI)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 99.75 |
|
UK Pound |
1 |
Rs. 153.00 |
|
Euro |
1 |
Rs. 130.35 |
Subject Company was established in 1992 and is engaged in manufacturing & marketing of Pharmaceutical Products. Market reputation is extremely good. Directors are reported as resourceful and experienced professionals. Trade relations are reported as fair. The Company can be considered for normal business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.95 |
|
UK Pound |
1 |
Rs.84.03 |
|
Euro |
1 |
Rs.70.72 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.